Dr
Harry Finch
Harry is Executive Vice President, Therapeutics of Argenta Discovery, having joined the company in October 2004 following the merger with Etiologics.
Harry has a long and prestigious career in chemistry, beginning aged 17 at Lancashire Tar Distillers, before joining Geigy. He has 54 patents and 56 publications to his name.
After his PhD from the University of Manchester and a brief interlude as a process chemist at Roche, he joined Allen & Hanburys. Harry worked his way up over 23 years from a bench scientist to Director of Chemistry (GlaxoWellcome, UK). Along the way he ran teams/groups of chemists/medicinal chemists ranging in size from 6 to 45, the Division being 284 strong. He also managed individual projects and portfolios of projects in a range of therapeutic areas (cardiovascular, gastrointestinal, inflammatory, respiratory, CNS, anti-infectives) and was a co-inventor of Salmeterol (Serevent; GSK), a successful long-acting bronchodilator for asthma.
Following the merger with SmithKline Beecham, Harry left GlaxoWellcome to take up a post of Research Director at Ribotargets (70 staff) where he was ultimately responsible for all research activities (chemistry, biology, CADD, structural biology).
Following two mergers, he began working part-time with Vernalis and consulted with a number of companies (including Etiologics) and investors over the summer of 2004.
Argenta Discovery Limited is a company incorporated and registered in England with registered number 3671653 whose registered office and principal place of business is at 8/9 Spire Green Centre, Flex Meadow, Harlow, CM19 5TR, United Kingdom and whose VAT registration number is GB 848 2268 02.